The impact of metformin on the development and course of anaplastic thyroid cancer in comparison to other histologic types of thyroid cancer

Anaplastic thyroid cancer (ATC) is the rarest (1–2%) form of cancer, but also most aggressive and associated with worst prognosis. The survival median rate 5–6 months, whereas only 20% patients survive more than one year from diagnosis, even though usage radiotherapy surgical resection. growing incidence ATC determine need for new prophylactic, diagnostic therapeutic solutions. Metformin was first introduced as an oral antidiabetic drug. beneficial effect metformin on anaplastic cells confirmed, however, mechanism this interaction still unclear. in prevention under discussion — nevertheless, studies conducted larger groups support impact, at least insulin resistance or metabolic syndrome. Both synergistic chemotherapy its protective are concerns additional confirmation randomized clinical trials. This review aims to sum up recent knowledge ATC.